Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.

Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ; West Coast Prostate Cancer Dream Team.

Eur Urol. 2019 Mar 27. pii: S0302-2838(19)30206-4. doi: 10.1016/j.eururo.2019.03.020. [Epub ahead of print]

PMID:
30928160
2.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Oct 18;175(3):889. doi: 10.1016/j.cell.2018.10.019. No abstract available.

3.

DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.

Lu E, Thomas GV, Chen Y, Wyatt AW, Lloyd P, Youngren J, Quigley D, Bergan R, Bailey S, Beer TM, Feng FY, Small EJ, Alumkal JJ.

J Natl Compr Canc Netw. 2018 Aug;16(8):933-937. doi: 10.6004/jnccn.2018.7020.

PMID:
30099369
4.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Jul 26;174(3):758-769.e9. doi: 10.1016/j.cell.2018.06.039. Epub 2018 Jul 19. Erratum in: Cell. 2018 Oct 18;175(3):889.

5.

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.

Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ.

J Clin Oncol. 2018 Aug 20;36(24):2492-2503. doi: 10.1200/JCO.2017.77.6880. Epub 2018 Jul 9.

6.

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.

Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx118.

7.

Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer.

Podolak J, Eilers K, Newby T, Slottke R, Tucker E, Olson SB, Lue HW, Youngren J, Aggarwal R, Small EJ, Graff JN, Alumkal JJ, Beer TM, Thomas GV.

Oncotarget. 2017 Mar 13;8(42):71447-71455. doi: 10.18632/oncotarget.16169. eCollection 2017 Sep 22.

8.

Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team.

Aggarwal R, Beer TM, Gleave M, Stuart JM, Rettig M, Evans CP, Youngren J, Alumkal JJ, Huang J, Thomas G, Witte O, Small EJ.

Eur Urol Focus. 2016 Dec;2(5):469-471. doi: 10.1016/j.euf.2016.10.011. Epub 2016 Nov 14.

PMID:
28723508
9.

Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer.

Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ.

Mol Cancer Res. 2017 Sep;15(9):1221-1229. doi: 10.1158/1541-7786.MCR-17-0196. Epub 2017 Jun 7.

10.

CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield.

Holmes MG, Foss E, Joseph G, Foye A, Beckett B, Motamedi D, Youngren J, Thomas GV, Huang J, Aggarwal R, Alumkal JJ, Beer TM, Small EJ, Link TM.

J Vasc Interv Radiol. 2017 Aug;28(8):1073-1081.e1. doi: 10.1016/j.jvir.2017.04.019. Epub 2017 May 24.

PMID:
28549709
11.

Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.

Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY.

Cancer Discov. 2017 Sep;7(9):999-1005. doi: 10.1158/2159-8290.CD-17-0146. Epub 2017 Apr 27.

12.

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.

Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell RH, Anderson SA, McConeghy B, Shukin R, Bazov J, Youngren J, Paris P, Thomas G, Small EJ, Wang Y, Gleave ME, Collins CC, Chi KN.

Clin Cancer Res. 2015 May 15;21(10):2315-24. doi: 10.1158/1078-0432.CCR-14-2666. Epub 2015 Feb 23.

13.

Insulin resistance induced by hyperinsulinemia coincides with a persistent alteration at the insulin receptor tyrosine kinase domain.

Catalano KJ, Maddux BA, Szary J, Youngren JF, Goldfine ID, Schaufele F.

PLoS One. 2014 Sep 26;9(9):e108693. doi: 10.1371/journal.pone.0108693. eCollection 2014.

14.

Chromium supplementation in non-obese non-diabetic subjects is associated with a decline in insulin sensitivity.

Masharani U, Gjerde C, McCoy S, Maddux BA, Hessler D, Goldfine ID, Youngren JF.

BMC Endocr Disord. 2012 Nov 30;12:31. doi: 10.1186/1472-6823-12-31.

15.

The effects of type 1 IGF receptor inhibition in a mouse model of diabetic kidney disease.

Troib A, Landau D, Youngren JF, Kachko L, Rabkin R, Segev Y.

Growth Horm IGF Res. 2011 Oct;21(5):285-91. doi: 10.1016/j.ghir.2011.07.007. Epub 2011 Aug 23.

16.

Insulin resistance in non-obese subjects is associated with activation of the JNK pathway and impaired insulin signaling in skeletal muscle.

Masharani UB, Maddux BA, Li X, Sakkas GK, Mulligan K, Schambelan M, Goldfine ID, Youngren JF.

PLoS One. 2011 May 11;6(5):e19878. doi: 10.1371/journal.pone.0019878.

17.

Synthesis of aryl-heteroaryl ureas (AHUs) based on 4-aminoquinoline and their evaluation against the insulin-like growth factor receptor (IGF-1R).

Engen W, O'Brien TE, Kelly B, Do J, Rillera L, Stapleton LK, Youngren JF, Anderson MO.

Bioorg Med Chem. 2010 Aug 15;18(16):5995-6005. doi: 10.1016/j.bmc.2010.06.071. Epub 2010 Jun 25.

18.

Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome.

Masharani U, Gjerde C, Evans JL, Youngren JF, Goldfine ID.

J Diabetes Sci Technol. 2010 Mar 1;4(2):359-64.

19.

Influence of gender on the relationship between insulin sensitivity, adiposity, and plasma lipids in lean nondiabetic subjects.

Masharani U, Goldfine ID, Youngren JF.

Metabolism. 2009 Nov;58(11):1602-8. doi: 10.1016/j.metabol.2009.05.012. Epub 2009 Jul 15.

20.

Nordihydroguaiaretic acid inhibits transforming growth factor beta type 1 receptor activity and downstream signaling.

Li F, Pham JD, Anderson MO, Youngren JF.

Eur J Pharmacol. 2009 Aug 15;616(1-3):31-7. doi: 10.1016/j.ejphar.2009.06.012. Epub 2009 Jun 17.

21.

Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells.

Ryan CJ, Zavodovskaya M, Youngren JF, Campbell M, Diamond M, Jones J, Shiry L, Allan G, Maddux BA, Goldfine ID.

Prostate. 2008 Aug 1;68(11):1232-40. doi: 10.1002/pros.20789.

PMID:
18491370
22.

A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.

Ryan CJ, Harzstark AH, Rosenberg J, Lin A, Claros C, Goldfine ID, Kerner JF, Small EJ, Youngren JF.

BJU Int. 2008 Feb;101(4):436-9. doi: 10.1111/j.1464-410X.2007.07330.x. Erratum in: BJU Int. 2008 Jun;101(11):1483. Youngren, Jack F [added].

23.

The role of membrane glycoprotein plasma cell antigen 1/ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities.

Goldfine ID, Maddux BA, Youngren JF, Reaven G, Accili D, Trischitta V, Vigneri R, Frittitta L.

Endocr Rev. 2008 Feb;29(1):62-75. doi: 10.1210/er.2007-0004. Epub 2008 Jan 16. Review. Erratum in: Endocr Rev. 2009 Feb;30(1):117.

24.

Technical evaluation of in vivo abdominal fat and IMCL quantification using MRI and MRSI at 3 T.

Li X, Youngren JF, Hyun B, Sakkas GK, Mulligan K, Majumdar S, Masharani UB, Schambelan M, Goldfine ID.

Magn Reson Imaging. 2008 Feb;26(2):188-97. Epub 2007 Aug 2.

25.

Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.

Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF, Goldfine ID.

J Cell Biochem. 2008 Feb 1;103(2):624-35.

PMID:
17562544
26.

Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs.

Blecha JE, Anderson MO, Chow JM, Guevarra CC, Pender C, Penaranda C, Zavodovskaya M, Youngren JF, Berkman CE.

Bioorg Med Chem Lett. 2007 Jul 15;17(14):4026-9. Epub 2007 Apr 29.

27.

Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells.

Meyer GE, Chesler L, Liu D, Gable K, Maddux BA, Goldenberg DD, Youngren JF, Goldfine ID, Weiss WA, Matthay KK, Rosenthal SM.

J Cell Biochem. 2007 Dec 15;102(6):1529-41.

28.

Regulation of insulin receptor function.

Youngren JF.

Cell Mol Life Sci. 2007 Apr;64(7-8):873-91. Review.

PMID:
17347799
29.

Parallel synthesis of diarylureas and their evaluation as inhibitors of insulin-like growth factor receptor.

Anderson MO, Yu H, Penaranda C, Maddux BA, Goldfine ID, Youngren JF, Guy RK.

J Comb Chem. 2006 Sep-Oct;8(5):784-90.

PMID:
16961415
30.

Expression of genes regulating malonyl-CoA in human skeletal muscle.

Pender C, Trentadue AR, Pories WJ, Dohm GL, Houmard JA, Youngren JF.

J Cell Biochem. 2006 Oct 15;99(3):860-7.

PMID:
16721829
31.

Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth.

Gable KL, Maddux BA, Penaranda C, Zavodovskaya M, Campbell MJ, Lobo M, Robinson L, Schow S, Kerner JA, Goldfine ID, Youngren JF.

Mol Cancer Ther. 2006 Apr;5(4):1079-86.

32.

Overexpression of the insulin receptor inhibitor PC-1/ENPP1 induces insulin resistance and hyperglycemia.

Maddux BA, Chang YN, Accili D, McGuinness OP, Youngren JF, Goldfine ID.

Am J Physiol Endocrinol Metab. 2006 Apr;290(4):E746-9. Epub 2005 Nov 8.

33.

Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.

Youngren JF, Gable K, Penaranda C, Maddux BA, Zavodovskaya M, Lobo M, Campbell M, Kerner J, Goldfine ID.

Breast Cancer Res Treat. 2005 Nov;94(1):37-46.

PMID:
16142439
34.

Analysis of insulin-stimulated insulin receptor activation and glucose transport in cultured skeletal muscle cells from obese subjects.

Pender C, Goldfine ID, Kulp JL, Tanner CJ, Maddux BA, MacDonald KG, Houmard JA, Youngren JF.

Metabolism. 2005 May;54(5):598-603.

PMID:
15877289
35.

Increased hepatic levels of the insulin receptor inhibitor, PC-1/NPP1, induce insulin resistance and glucose intolerance.

Dong H, Maddux BA, Altomonte J, Meseck M, Accili D, Terkeltaub R, Johnson K, Youngren JF, Goldfine ID.

Diabetes. 2005 Feb;54(2):367-72.

36.

Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling.

Corbould A, Kim YB, Youngren JF, Pender C, Kahn BB, Lee A, Dunaif A.

Am J Physiol Endocrinol Metab. 2005 May;288(5):E1047-54. Epub 2004 Dec 21.

37.

Effective treatments for insulin resistance: trim the fat and douse the fire.

Evans JL, Youngren JF, Goldfine ID.

Trends Endocrinol Metab. 2004 Nov;15(9):425-31. Review.

PMID:
15519889
38.

Muscle insulin receptor concentrations in obese patients post bariatric surgery: relationship to hyperinsulinemia.

Pender C, Goldfine ID, Tanner CJ, Pories WJ, MacDonald KG, Havel PJ, Houmard JA, Youngren JF.

Int J Obes Relat Metab Disord. 2004 Mar;28(3):363-9.

PMID:
14724657
39.

Decreased insulin receptor (IR) autophosphorylation in fibroblasts from patients with PCOS: effects of serine kinase inhibitors and IR activators.

Li M, Youngren JF, Dunaif A, Goldfine ID, Maddux BA, Zhang BB, Evans JL.

J Clin Endocrinol Metab. 2002 Sep;87(9):4088-93.

PMID:
12213853
40.

Regulation of insulin receptor function by a small molecule insulin receptor activator.

Pender C, Goldfine ID, Manchem VP, Evans JL, Spevak WR, Shi S, Rao S, Bajjalieh S, Maddux BA, Youngren JF.

J Biol Chem. 2002 Nov 15;277(46):43565-71. Epub 2002 Sep 3.

41.

Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans.

Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C, Tataranni PA.

Diabetes. 2002 Jun;51(6):1884-8.

42.

Elevated plasma cell membrane glycoprotein levels and diminished insulin receptor autophosphorylation in obese, insulin-resistant rhesus monkeys.

Pender C, Ortmeyer HK, Hansen BC, Goldfine ID, Youngren JF.

Metabolism. 2002 Apr;51(4):465-70.

PMID:
11912555
43.

Impaired insulin-receptor autophosphorylation is an early defect in fat-fed, insulin-resistant rats.

Youngren JF, Paik J, Barnard RJ.

J Appl Physiol (1985). 2001 Nov;91(5):2240-7.

44.

Small molecule insulin receptor activators potentiate insulin action in insulin-resistant cells.

Li M, Youngren JF, Manchem VP, Kozlowski M, Zhang BB, Maddux BA, Goldfine ID.

Diabetes. 2001 Oct;50(10):2323-8.

45.

Enhanced muscle insulin receptor autophosphorylation with short-term aerobic exercise training.

Youngren JF, Keen S, Kulp JL, Tanner CJ, Houmard JA, Goldfine ID.

Am J Physiol Endocrinol Metab. 2001 Mar;280(3):E528-33.

47.

Role of PC-1 in the etiology of insulin resistance.

Goldfine ID, Maddux BA, Youngren JF, Trischitta V, Frittitta L.

Ann N Y Acad Sci. 1999 Nov 18;892:204-22. Review.

PMID:
10842664
48.

Insulin receptor autophosphorylation in cultured myoblasts correlates to glucose disposal in Pima Indians.

Youngren JF, Goldfine ID, Pratley RE.

Am J Physiol. 1999 May;276(5):E990-4. doi: 10.1152/ajpendo.1999.276.5.E990.

PMID:
10329994
49.

Membrane glycoprotein PC-1 and insulin resistance.

Goldfine ID, Maddux BA, Youngren JF, Frittitta L, Trischitta V, Dohm GL.

Mol Cell Biochem. 1998 May;182(1-2):177-84. Review.

PMID:
9609127
50.

Contributions of the American Journal of Physiology to the discovery of insulin.

Goldfine ID, Youngren JF.

Am J Physiol. 1998 Feb;274(2):E207-9. doi: 10.1152/ajpendo.1998.274.2.E207. Review.

PMID:
9486148

Supplemental Content

Loading ...
Support Center